Core Viewpoint - 博瑞医药 has experienced a stock price increase and has announced a delay in several fundraising projects, which will not affect the company's normal operations or the intended use of funds [1][2][3]. Group 1: Stock Performance - As of December 26, 2025, 博瑞医药's stock closed at 50.21 yuan, up 3.31% from the previous week [1]. - The stock reached a high of 50.97 yuan and a low of 48.22 yuan during the week [1]. - The company's total market capitalization is 20.757 billion yuan, ranking 22nd in the chemical pharmaceutical sector and 947th among all A-shares [1]. Group 2: Company Announcements - 国联民生证券 conducted a site inspection for 博瑞医药's 2025 annual continuous supervision, finding no violations in governance, information disclosure, or major investments [2][6]. - 博瑞医药's board approved a resolution to postpone the expected operational status date for several fundraising projects to March 2027 due to pending product approvals and the addition of an automated warehouse [2][3]. - The delay affects projects including the inhalation and chemical drug formulation production base and the biopharmaceutical R&D center [2][3]. Group 3: Internal Governance - 博瑞医药 has established an internal audit system to oversee internal controls, financial information, and operational activities [4]. - The company has implemented a management system for forward foreign exchange transactions to mitigate exchange rate risks [4]. - A fundraising management method has been developed to ensure that raised funds are used specifically for intended projects and are subject to strict oversight [5][6]. Group 4: Management Regulations - 博瑞医药 has set up a management system for shares held by directors and senior management, regulating trading periods and disclosure requirements [7].